bpc-157 mechanism of action tendon healing studies BPC-157: Repair and More Gastric pentadecapeptide body protection compound
Description
Key features of Phase 0 first-in-human trial with imaging A Phase 0 trial is always conducted on a small group of participants
Protocol: DSIP 200 mcg subcutaneously before bed
Therefore, the first two doses prior to midnight would be reported with codes 96365 and 96366, respectively
Document in log
